Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs.

abstract：:We have investigated the absorption and urinary excretion of tripotassium dicitrato bismuthate during a treatment course of 4 weeks in 7 patients with normal renal function (creatinine clearance 115 +/- 29 ml/min; mean +/- S.D.), in 7 patients with impaired renal function (creatinine clearance = 34 +/- 19 ml/min) and ...

journal_title：Alimentary pharmacology & therapeutics

authors： Treiber G,Gladziwa U,Ittel TH,Walker S,Schweinsberg F,Klotz U

更新日期：1991-10-01 00:00:00

abstract：:More than 15 years after the launch of omeprazole in 1988, proton-pump inhibitors remain central to the management of acid-suppression disorders and are unchallenged with regard to their efficacy and popularity among doctors and patients. They are considered safe despite early concerns about the possibility of an asso...

journal_title：Alimentary pharmacology & therapeutics

authors： Raghunath AS,O'Morain C,McLoughlin RC

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:Different authors have postulated both toxic and protective effects for nitric oxide (NO) in the pathophysiology of active inflammation. AIM:To examine the role of NO, especially that produced by the inducible form of nitric oxide synthase (iNOS), by investigating the effects of NOS inhibitors and NO donors...

journal_title：Alimentary pharmacology & therapeutics

authors： Yoshida Y,Iwai A,Itoh K,Tanaka M,Kato S,Hokari R,Miyahara T,Koyama H,Miura S,Kobayashi M

更新日期：2000-04-01 00:00:00

abstract：BACKGROUND:Although incrimination of the intestinal microbiota in the pathogenesis of IBD is widely accepted, few data are available about the role of specific bacteria. Potentially, Faecalibacterium prausnitzii, bacteria with anti-inflammatory properties, might be deficient in ulcerative colitis (UC). AIM:To quantify...

journal_title：Alimentary pharmacology & therapeutics

authors： Varela E,Manichanh C,Gallart M,Torrejón A,Borruel N,Casellas F,Guarner F,Antolin M

更新日期：2013-07-01 00:00:00

abstract：:The decision regarding prophylactic treatment after surgery in Crohn's disease (CD) requires a good estimation of the risk of recurrence. It is also important to consider the consequences of recurrence for the patient, and the risks and benefits of treatment, bearing in mind that it will be given over a long period. S...

journal_title：Alimentary pharmacology & therapeutics

authors： Lémann M

更新日期：2006-10-01 00:00:00

abstract：BACKGROUND:Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab. AIM:To evaluate the indications for adalimumab, the proportion of inflammatory bowel disease patients who requir...

journal_title：Alimentary pharmacology & therapeutics

authors： Swaminath A,Ullman T,Rosen M,Mayer L,Lichtiger S,Abreu MT

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely. This may be the reason for the general failure of acid suppression in clinical trials in these patients. It may be more rewarding to identify true responders to drug treatment by a single subject trial. ...

journal_title：Alimentary pharmacology & therapeutics

authors： Bytzer P,Hansen JM,Rune S,Bonnevie O,Breinstrup H,Funch-Jensen P,Matzen P,Meineche-Schmidt V,Schaffalitzky De Muckadell OB

更新日期：2000-11-01 00:00:00

abstract：:An analysis carried out in 1994 by the WHO International Agency for Research on Cancer (IARC) resulted in Helicobacter pylori being designated as a Group 1 carcinogen and thus clearly having an association with the development of gastric cancer. In the case of H. pylori, the evaluation was made solely on the basis of ...

journal_title：Alimentary pharmacology & therapeutics

authors： Asaka M,Kudo M,Kato M,Sugiyama T,Takeda H

更新日期：1998-02-01 00:00:00

abstract：:In a double-blind randomized study, the profile of 24-h intragastric acidity and nocturnal gastric secretion was measured in a group of patients with healed gastric ulcer on placebo and 400 mg cimetidine b.d. and 800 mg nocte. Neither cimetidine regimen significantly decreased daytime intragastric acidity, but the 800...

journal_title：Alimentary pharmacology & therapeutics

authors： Derodra JK,Howden CW,Burget DW,Hunt RH

更新日期：1990-06-01 00:00:00

abstract：BACKGROUND:Considerable information has been gathered on the functional organization of enteric neuronal circuitries regulating gastrointestinal motility. However, little is known about the neuropathophysiological mechanisms underlying gastrointestinal motor disorders. AIM:To analyse the most important pathological fi...

journal_title：Alimentary pharmacology & therapeutics

authors： Di Nardo G,Blandizzi C,Volta U,Colucci R,Stanghellini V,Barbara G,Del Tacca M,Tonini M,Corinaldesi R,De Giorgio R

更新日期：2008-07-01 00:00:00

abstract：BACKGROUND:Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited. AIM:To investigate the efficacy and safety of adalimumab in the clinical setting. METHODS...

journal_title：Alimentary pharmacology & therapeutics

authors： Ho GT,Smith L,Aitken S,Lee HM,Ting T,Fennell J,Lees CW,Palmer KR,Penman ID,Shand AG,Arnott ID,Satsangi J

更新日期：2008-02-15 00:00:00

abstract：BACKGROUND:Glucocorticoids have been shown to induce peptic ulcers, especially when co-administered with NSAIDs. Hepatocyte growth factor (HGF) plays a role in gastric ulcer repair, facilitating the restitution of gastric mucosal epithelial cells. HGF expression is induced by PGs in gastric fibroblasts. We hypothesized...

journal_title：Alimentary pharmacology & therapeutics

authors： Takahashi M,Takada H,Takagi K,Kataoka S,Soma R,Kuwayama H

更新日期：2003-07-01 00:00:00

abstract：BACKGROUND:Triple therapy (proton pump inhibitor, clarithromycin and amoxicillin or an imidazole) is the first-line treatment for Helicobacter pylori infection. However, the effectiveness of triple therapy is decreasing due to the increase in antibiotic resistance. Quadruple therapy (proton pump inhibitor, tetracycline...

journal_title：Alimentary pharmacology & therapeutics

authors： Gené E,Calvet X,Azagra R,Gisbert JP

更新日期：2003-05-01 00:00:00

abstract：BACKGROUND:Many patients are not symptom-free after eradication therapy for Helicobacter pylori and continue to use proton pump inhibitors or H2-receptor antagonists (H2-RAs). AIM:To ascertain whether a cohort of patients treated for H. pylori were still taking either proton pump inhibitors or H2-RAs more than 4 years...

journal_title：Alimentary pharmacology & therapeutics

authors： Tan AC,Hartog GD,Mulder CJ

更新日期：1999-11-01 00:00:00

abstract：BACKGROUND:Functional dyspepsia is a problem that is difficult to treat in clinical practice. AIM:To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia. METHODS:Patients with functional dyspepsia (n=557) were divided a priori into two studies by Helicobacter pylori status, ...

journal_title：Alimentary pharmacology & therapeutics

authors： Talley NJ,Riff DS,Schwartz H,Marcuard SP

更新日期：2001-10-01 00:00:00

abstract：AIM:To assess the decline in Helicobacter pylori antibodies after eradication of infection. METHODS:The H. pylori status was determined at entry (D0) by culture and histology performed on antral biopsies and after eradication treatment at day 42 (day 42) and after 6 months (M6) by the 13C-urea breath test. The EIA kit...

journal_title：Alimentary pharmacology & therapeutics

authors： Bergey B,Marchildon P,Peacock J,Mégraud F

更新日期：2003-09-15 00:00:00

abstract：:Intestinal failure is a specific disease entity resulting from intestinal resection or disease-associated malabsorption and characterized by the inability to maintain protein-energy, fluid, electrolyte or micronutrient balance. We performed a MEDLINE search (1966-2006) to identify relevant articles, using keywords int...

journal_title：Alimentary pharmacology & therapeutics

authors： Lal S,Teubner A,Shaffer JL

更新日期：2006-07-01 00:00:00

abstract：BACKGROUND:Deregulation of mammalian target of rapamycin (mTOR) signalling is common in human hepatocellular carcinoma (HCC). AIM:To determine the maximum tolerated dose (MTD) of the oral mTOR inhibitor everolimus in advanced HCC patients. METHODS:Patients with locally advanced or metastatic HCC (Child-Pugh class A o...

journal_title：Alimentary pharmacology & therapeutics

authors： Shiah HS,Chen CY,Dai CY,Hsiao CF,Lin YJ,Su WC,Chang JY,Whang-Peng J,Lin PW,Huang JD,Chen LT

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:The best technique to estimate portal hypertension (PHT) is to measure the hepatic venous pressure gradient (HVPG), which is an invasive method. AIM:To assess the relationship between the Fibrotest (Biopredictive, Paris, France) and the presence and degree of PHT in patients with liver disease, and to deter...

journal_title：Alimentary pharmacology & therapeutics

authors： Thabut D,Imbert-Bismut F,Cazals-Hatem D,Messous D,Muntenau M,Valla DC,Moreau R,Poynard T,Lebrec D

更新日期：2007-08-01 00:00:00

abstract：BACKGROUND:Acute liver failure is a rare and devastating clinical condition resulting from sudden loss of hepatic parenchyma and metabolic function. The Scottish Liver Transplant Unit (SLTU) offers specialist management and emergency liver transplantation to patients with acute liver failure from across Scotland. AIM:...

journal_title：Alimentary pharmacology & therapeutics

authors： Donnelly MC,Davidson JS,Martin K,Baird A,Hayes PC,Simpson KJ

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Therapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA-based, with a turnaround time ...

journal_title：Alimentary pharmacology & therapeutics

authors： Afonso J,Lopes S,Gonçalves R,Caldeira P,Lago P,Tavares de Sousa H,Ramos J,Gonçalves AR,Ministro P,Rosa I,Vieira AI,Dias CC,Magro F,Portuguese IBD Study Group (GEDII).

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:The presence of the gastric pathogen, Helicobacter pylori influences acid suppression by proton pump inhibitors and treatment outcome in patients with gastro-oesophageal reflux disease. AIM:To determine the influence of H. pylori infection on effectiveness of rabeprazole in primary and secondary care patien...

journal_title：Alimentary pharmacology & therapeutics

authors： Wit NJ,Boer WA,Geldof H,Hazelhoff B,Bergmans P,Tytgat GN,Smout AJ

更新日期：2004-08-15 00:00:00

abstract：BACKGROUND:Surveillance colonoscopy is recommended for inflammatory bowel disease (IBD) patients with longstanding extensive colitis (LEC). AIMS:To assess modalities and results of colonoscopic surveillance in a subset of CESAME cohort patients at high risk of colorectal cancer (CRC) and followed in university French ...

journal_title：Alimentary pharmacology & therapeutics

authors： Vienne A,Simon T,Cosnes J,Baudry C,Bouhnik Y,Soulé JC,Chaussade S,Marteau P,Jian R,Delchier JC,Coffin B,Admane H,Carrat F,Drouet E,Beaugerie L

更新日期：2011-07-01 00:00:00

abstract：BACKGROUND:A high proportion of patients with inflammatory bowel disease (IBD) do not achieve clinical remission with the current therapies including mesalazine (mesalamine), immunossupresants (IMS) and antibodies against tumour necrosis factor (anti-TNF). Moreover, IMS and anti-TNF involve a nonnegligible risk for inf...

journal_title：Alimentary pharmacology & therapeutics

authors： Lobatón T,Vermeire S,Van Assche G,Rutgeerts P

更新日期：2014-03-01 00:00:00

abstract：AIM:To appraise the tolerance and efficacy of an induction of tolerance protocol to infliximab permitting the re-administration of the drug to patients with Crohn's disease having had infusion reactions requiring suspension of treatment. METHODS:Fourteen patients were included in the induction of tolerance protocol. E...

journal_title：Alimentary pharmacology & therapeutics

authors： Duburque C,Lelong J,Iacob R,Seddik M,Desreumaux P,Fournier C,Wallaert B,Cortot A,Colombel JF

更新日期：2006-09-01 00:00:00

abstract：BACKGROUND:Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. AIM:To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent...

journal_title：Alimentary pharmacology & therapeutics

authors： Watanabe M,Nishino H,Sameshima Y,Ota A,Nakamura S,Hibi T

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Abnormal barrier function may be genetically determined in Crohn's disease. AIM:To examine the role of abnormal intestinal permeability in genetic predisposition in multiplex vs. sporadic Crohn's disease families. METHODS:Intestinal permeability was measured in patients, relatives and partners by means of ...

journal_title：Alimentary pharmacology & therapeutics

authors： D'Incà R,Annese V,di Leo V,Latiano A,Quaino V,Abazia C,Vettorato MG,Sturniolo GC

更新日期：2006-05-15 00:00:00

abstract：BACKGROUND:Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited. AIM:To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof. METHO...

journal_title：Alimentary pharmacology & therapeutics

authors： Lin M,Kramer J,White D,Cao Y,Tavakoli-Tabasi S,Madu S,Smith D,Asch SM,El-Serag HB,Kanwal F

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Benign epithelial gastric polyps have been reported to be more common in atrophic body gastritis. The role of Helicobacter pylori infection in the induction of gastric atrophy is well-known. The development of hyperplastic polyps may be in relation to H. pylori infection. AIM:To investigate occurrence of be...

journal_title：Alimentary pharmacology & therapeutics

authors： Di Giulio E,Lahner E,Micheletti A,Milione M,D'Ambra G,Bordi C,Delle Fave G,Annibale B

更新日期：2005-03-01 00:00:00

abstract：:Both duodenal and gastric ulcer disease are closely associated with Helicobacter pylori infection. An infected individual has an estimated lifetime risk of 10-20% for the development of peptic ulcer disease, which is at least 3-4 fold higher than in non-infected subjects. H. pylori infection can be diagnosed in 90-100...

journal_title：Alimentary pharmacology & therapeutics

authors： Kuipers EJ,Thijs JC,Festen HP

更新日期：1995-01-01 00:00:00